Recruitment experience in a phase 0 trial of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients (pts) with advanced malignancies

被引：0
|
作者：
Gutierrez, M.
Kummar, S.
Horneffer, Y.
Juwara, L.
Chen, A.
Melillo, G.
Pickeral, O.
Tomaszewski, J. E.
Murgo, A. J.
Doroshow, J. H.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] SAIC Frederick Inc, Frederick, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14111
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia
    Liu, Stanley K.
    Coackley, Carla
    Krause, Mechthild
    Jalali, Farid
    Chan, Norman
    Bristow, Robert G.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 (02) : 258 - 268
  • [22] Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells
    Hsu, Heng-Wei
    de Necochea-Campion, Rosalia
    Williams, Vonetta
    Duerksen-Hughes, Penelope J.
    Simental, Alfred A., Jr.
    Ferris, Robert L.
    Chen, Chien-Shing
    Mirshahidi, Saied
    ORAL ONCOLOGY, 2014, 50 (07) : 662 - 669
  • [23] Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles
    Munoz-Gamez, Jose A.
    Lopez Viota, Julian
    Barrientos, Andres
    Carazo, Angel
    Sanjuan-Nunez, Laura
    Quiles-Perez, Rosa
    Munoz-de-Rueda, Paloma
    Delgado, Angel
    Ruiz-Extremera, Angeles
    Salmeron, Javier
    LIVER INTERNATIONAL, 2015, 35 (04) : 1430 - 1441
  • [24] Disposition and Drug-Drug Interaction Potential of Veliparib (ABT-888), a Novel and Potent Inhibitor of Poly(ADP-ribose) Polymerase
    Li, Xiaofeng
    Delzer, Juergen
    Voorman, Richard
    de Morais, Sonia M.
    Lao, Yanbin
    DRUG METABOLISM AND DISPOSITION, 2011, 39 (07) : 1161 - 1169
  • [25] ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
    Donawho, Cherrie K.
    Luo, Yan
    Luo, Yanping
    Penning, Thomas D.
    Bauch, Joy L.
    Bouska, Jennifer J.
    Bontcheva-Diaz, Velitchka D.
    Cox, Bryan F.
    DeWeese, Theodore L.
    Dillehay, Larry E.
    Ferguson, Debra C.
    Ghoreishi-Haack, Nayereh S.
    Grimm, David R.
    Guan, Ran
    Han, Edward K.
    Holley-Shanks, Rhonda R.
    Hristov, Boris
    Idler, Kenneth B.
    Jarvis, Ken
    Johnson, Eric F.
    Kleinberg, Lawrence R.
    Klinghofer, Vered
    Lasko, Loren M.
    Liu, Xuesong
    Marsh, Kennan C.
    McGonigal, Thomas P.
    Meulbroek, Jonathan A.
    Olson, Amanda M.
    Palma, Joann P.
    Rodriguez, Luis E.
    Shi, Yan
    Stavropoulos, Jason A.
    Tsurutani, Alan C.
    Zhu, Gui-Dong
    Rosenberg, Saul H.
    Giranda, Vincent L.
    Frost, David J.
    CLINICAL CANCER RESEARCH, 2007, 13 (09) : 2728 - 2737
  • [26] Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias
    Karp, Judith E.
    Pratz, Keith W.
    Litzow, Mark R.
    Ji, Juping
    Chen, Alice
    Rudek, Michelle
    Kaufmann, Scott H.
    BLOOD, 2010, 116 (21) : 1342 - 1343
  • [27] A Biomarker Study of Poly(ADP-ribose) Polymerase Inhibitor (PARPi) ABT-888 Activity On Ex Vivo Tissue From Ovarian Cancer Patients
    Weberpals, J.
    Ma, X.
    Dimitroulakos, J.
    Djordjevic, B.
    Lapointe-Milot, K.
    Al Mutairi, N.
    Pelletier, L.
    Oza, A.
    Squire, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 146 - 146
  • [28] Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors.
    LoRusso, P.
    Ji, J. J.
    Li, J.
    Heilbrun, K.
    Shapiro, G.
    Sausville, E. A.
    Boerner, S. A.
    Smith, D. W.
    Pilat, M. J.
    Zhang, J.
    Chen, A. P.
    Nechiporchik, N.
    Parchment, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888
    Tuli, Richard
    Surmak, Andrew J.
    Reyes, Juvenal
    Armour, Michael
    Hacker-Prietz, Amy
    Wong, John
    DeWeese, Theodore L.
    Herman, Joseph M.
    TRANSLATIONAL ONCOLOGY, 2014, 7 (03): : 439 - 445
  • [30] Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias
    Pratz, Keith W.
    Kaufmann, Scott H.
    Litzow, Mark R.
    Ji, Jiuping
    Chen, Alice
    Rudek, Michelle A.
    Karp, Judith E.
    BLOOD, 2011, 118 (21) : 1552 - 1552
12345